{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:33Z","timestamp":1786993473773,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jvacx.2019.100033","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T11:49:56Z","timestamp":1563450596000},"page":"100033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Shaping markets to benefit global health \u2013 A 15-year history and lessons learned from the pentavalent vaccine market"],"prefix":"10.1016","volume":"2","author":[{"given":"Melissa","family":"Malhame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kalpaxis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Momeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2019.100033_b0005","unstructured":"Barder O, Kremer M, Levine R. Making Markets for Vacccines: Ideas to action Washington DC; 2005."},{"key":"10.1016\/j.jvacx.2019.100033_b0010","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1377\/hlthaff.24.3.690","article-title":"The problems and promise of vaccine markets in developing countries","volume":"24","author":"Batson","year":"2005","journal-title":"Health Aff"},{"key":"10.1016\/j.jvacx.2019.100033_b0015","unstructured":"Gavi. The vaccine alliance. GAVI alliance vaccine supply and procurement strategy for the period 2011-2015. Geneva: 2011."},{"key":"10.1016\/j.jvacx.2019.100033_b0020","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12889-015-2521-8","article-title":"Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies strategies and resource allocation mechanisms thr","volume":"15","author":"Gandhi","year":"2015","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.jvacx.2019.100033_b0025","unstructured":"Gavi. The vaccine alliance. Gavi, The vaccine alliance: supply and procurement strategy 2016-20. Geneva: 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0030","unstructured":"(Philadelphia) (Children\u2019s Hospital of. Vaccine history n.d. https:\/\/www.chop.edu.centers-programs\/vaccine-education-center\/vaccine-history\/dveelopments-by-year [accessed August 3, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0035","doi-asserted-by":"crossref","DOI":"10.4161\/hv.6.12.13076","article-title":"A policy framework for accelerating adoption of new vaccines","author":"Levine","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jvacx.2019.100033_b0040","unstructured":"WHO. African Region Immunization Profile. Geneva: 2018."},{"key":"10.1016\/j.jvacx.2019.100033_b0045","unstructured":"Gavi. Haemophilus influenzae type b vaccine support 2009. https:\/\/www.gavi.org\/support\/nvs\/hib\/ [accessed September 6, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0050","unstructured":"CEPA LLP. GAVI second evaluation report. London: 2010."},{"key":"10.1016\/j.jvacx.2019.100033_b0055","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.16.178475","article-title":"Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001\u20132020","author":"Ozawa","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jvacx.2019.100033_b0060","unstructured":"Chee G, Molldrem V, Hsi N, Chankova S. Evaluation of GAVI Phase 1 Performance. Bethesda, MD: 2008."},{"key":"10.1016\/j.jvacx.2019.100033_b0065","unstructured":"Gavi. The Vaccine Alliance. All countries committments and disbursementsNo Title 2019. https:\/\/www.gavi.org\/country\/all-countries-commitments-and-disbursements\/."},{"key":"10.1016\/j.jvacx.2019.100033_b0070","unstructured":"WHO. Prequalification to make high-quality, safe and affordable vaccines 2013. www.who.int\/features\/2013\/vaccine_prequalification\/en\/."},{"key":"10.1016\/j.jvacx.2019.100033_b0075","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1098\/rstb.2011.0040","article-title":"Contribution of the GAVI Alliance to improving health and reducing poverty","volume":"366","author":"Lob-Levyt","year":"2011","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"10.1016\/j.jvacx.2019.100033_b0080","unstructured":"UNICEF. Vaccine Security: ensuring a sustained, uninterrupted supply of affordable vaccines. 2002."},{"key":"10.1016\/j.jvacx.2019.100033_b0085","unstructured":"Gavi. Supply Strategy for Hib and Hep B Containing Vaccines. 2005."},{"key":"10.1016\/j.jvacx.2019.100033_b0090","unstructured":"UNICEF. Market Influencing 2018. https:\/\/www.unicef.org\/supply\/index_102742.html."},{"key":"10.1016\/j.jvacx.2019.100033_b0095","unstructured":"Gavi. The Vaccine Alliance. Healthy Markets Framework - public overview. 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0100","unstructured":"UNICEF. Pentavalent Vaccine: Market & Supply Update. Copenhagen: 2015."},{"key":"10.1016\/j.jvacx.2019.100033_b0105","unstructured":"Gavi role in every growing demand for pentavalent 2009. https:\/\/www.gavi.org\/library\/news\/roi\/2009\/gavi-role-in-ever-growing-demand-for-pentavalent."},{"key":"10.1016\/j.jvacx.2019.100033_b0110","unstructured":"UNICEF. Pentavalent Vaccine: Market & Supply Update. Copenhagen: 2017."},{"key":"10.1016\/j.jvacx.2019.100033_b0115","unstructured":"WHO. SHAN5 VACCINE DELISTED FROM WHO PREQUALIFICATION 2010. http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/shan5_who_statement_27july10.pdf?ua=1."},{"key":"10.1016\/j.jvacx.2019.100033_b0120","unstructured":"UNICEF. Pentavalent Price Update 2017. https:\/\/www.unicef.org\/supply\/files\/Penta_Price_Update_17_10_06.pdf [accessed July 28, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0125","unstructured":"Personal Communication 2018."},{"key":"10.1016\/j.jvacx.2019.100033_b0130","unstructured":"Gavi. Market Development of HepB\/Hib containing vaccines 2001-09: experiences from three procurement rounds. Geneva: 2007."},{"key":"10.1016\/j.jvacx.2019.100033_b0135","unstructured":"UNICEF. PRODUCT MENU 2010 2010. https:\/\/www.unicef.org\/supply\/files\/Product_Menu_Nov_2010_Published.pdf [accessed November 18, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0140","unstructured":"WHO. Panacea Biotec DTP-based combination and monovalent hepatitis B vaccines delisted from WHO list of prequalified vaccines 2011. www.who.int\/immunization_standards\/vaccine_quality\/DTP_mono_hepb_aug2011\/en\/."},{"key":"10.1016\/j.jvacx.2019.100033_b0145","unstructured":"Pentavalent vaccine 30 percent price drop 2013. https:\/\/www.gavi.org\/library\/news\/press-releases\/2013\/pentavalent-vaccine-30-percent-price-drop\/ [accessed August 2, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0150","unstructured":"Revelle N. Smart strategies and collaboration can help improve global health. STATnews 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0155","unstructured":"Gavi The Vaccine Alliance. Supply and Procurement Roadmap, Pentavalent. Geneva: 2013."},{"key":"10.1016\/j.jvacx.2019.100033_b0160","unstructured":"UNICEF. Request for Proposals DAN-2012-501392. Copenhagen: 2012."},{"key":"10.1016\/j.jvacx.2019.100033_b0165","unstructured":"Gavi The Vaccine Alliance. Supply and Procurement Roadmap, Pentavalent. Geneva: 2014."},{"key":"10.1016\/j.jvacx.2019.100033_b0170","unstructured":"UNICEF. Annual Supply Report. 2014."},{"key":"10.1016\/j.jvacx.2019.100033_b0175","unstructured":"UNICEF. UNICEF Supply Division Pricing Data 2018."},{"key":"10.1016\/j.jvacx.2019.100033_b0180","unstructured":"Private sector pledges 2015. https:\/\/www.gavi.org\/library\/news\/press-releases\/2015\/private-sector-makes-new-pledges-to-support-childhood-immunisation-in-developing-countries\/ [accessed August 2, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0185","unstructured":"BE receives an order n.d. http:\/\/www.biologicale.com\/news.html."},{"key":"10.1016\/j.jvacx.2019.100033_b0190","unstructured":"UNICEF. Pentavalent Price Update, 2019. 2019."},{"key":"10.1016\/j.jvacx.2019.100033_b0195","unstructured":"Gavi The Vaccine Alliance. Supply and Procurement Roadmap, Pentavalent. Gen: 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0200","unstructured":"UNICEF. Request for Proposals DAN-2016-502178. Copenhagen: 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0205","unstructured":"UNICEF. Pentavalent Pricing Data. Copenhagen: 2016."},{"key":"10.1016\/j.jvacx.2019.100033_b0210","unstructured":"ILL launches Vaxtar5 pentavalent. PharmaInsider 2018. http:\/\/pharmainsider.in\/iil-launches-vaxtar-5-pentavalent-vaccine\/ [accessed September 2, 2018]."},{"key":"10.1016\/j.jvacx.2019.100033_b0215","doi-asserted-by":"crossref","DOI":"10.1093\/heapol\/czs123","article-title":"Lessons learned in shaping vaccine markets in low-income countries: A review of the vaccine market segment supported by the GAVI Alliance","author":"Gilchrist","year":"2013","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jvacx.2019.100033_b0225","unstructured":"Gavi The Vaccine Alliance. Gavi Market Shaping Indicators 2016-20 n.d. https:\/\/www.gavi.org\/results\/measuring\/2016-2020-indicators\/market-shaping-goal\/ [accessed October 14, 2018]."}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136219300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136219300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:04:26Z","timestamp":1762913066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136219300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":44,"alternative-id":["S2590136219300348"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100033","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shaping markets to benefit global health \u2013 A 15-year history and lessons learned from the pentavalent vaccine market","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2019.100033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100033"}}